CD8A and neoplasm: AMD3100 (10 mg/kg) was administered intraperitoneally to LLC1‐bearing mice at ZT4 or ZT16, corresponding to the time points just before the trough and peak of CXCR4 expression in tumor‐infiltrated CD8+ T cells, respectively.